Entellus Medical, Inc. (NASDAQ:ENTL) has earned a consensus rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $21.20.

Several equities analysts recently issued reports on ENTL shares. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub upgraded Entellus Medical from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 14th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research report on Tuesday, August 22nd.

Entellus Medical (ENTL) opened at 19.50 on Wednesday. The firm’s market capitalization is $494.73 million. Entellus Medical has a 1-year low of $12.31 and a 1-year high of $22.57. The company has a 50-day moving average price of $17.67 and a 200 day moving average price of $17.67.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). The firm had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. Entellus Medical’s revenue was up 18.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.27) EPS. Analysts expect that Entellus Medical will post ($1.61) earnings per share for the current fiscal year.

In related news, VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total transaction of $36,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Stephen R. Paidosh sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total transaction of $438,500.00. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Swiss National Bank raised its holdings in Entellus Medical by 98.9% in the 1st quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after acquiring an additional 8,800 shares during the last quarter. TD Asset Management Inc. purchased a new position in shares of Entellus Medical during the 1st quarter worth $279,000. Parametric Portfolio Associates LLC lifted its stake in shares of Entellus Medical by 5.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after purchasing an additional 573 shares during the period. Royce & Associates LP lifted its stake in shares of Entellus Medical by 288.4% during the 1st quarter. Royce & Associates LP now owns 167,000 shares of the medical technology company’s stock worth $2,305,000 after purchasing an additional 124,000 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Entellus Medical by 77.8% during the first quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock worth $5,862,000 after purchasing an additional 185,833 shares during the last quarter. 70.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Entellus Medical, Inc. (ENTL) Given Average Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/entellus-medical-inc-entl-given-average-recommendation-of-hold-by-analysts.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.